Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Tubulis GmbH has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners and 2 distinct art units, which indicates that the active files are separated across examination assignments.
HOPKINS, SAMANTHA LAKE is the busiest examiner, with 1 pending action. Response planning should therefore account for the individual examiner contexts rather than assume a common prosecution channel.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOPKINS, SAMANTHA LAKE | 1 | 60.7% | +61.5% |
| MARVICH, MARIA | 1 | 55.0% | +27.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18489624 | NOVEL ANTIBODY DRUG CONJUGATES WITH NOVEL NAPI2B ANTIBODIES, THERAPEUTIC METHODS AND USES THEREOF | HOPKINS, SAMANTHA LAKE | — |
| 18054063 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A CAMPTOTHECIN MOIETY | MARVICH, MARIA | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18489624 | NOVEL ANTIBODY DRUG CONJUGATES WITH NOVEL NAPI2B ANTIBODIES, THERAPEUTIC METHODS AND USES THEREOF | HOPKINS, SAMANTHA LAKE | 1641 | Other | Non-Final OA | — | Pending | Oct 18, 2023 |
| 18054063 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A CAMPTOTHECIN MOIETY | MARVICH, MARIA | 1634 | DP | Final Rejection | — | Pending | Nov 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTubulis GmbH has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Samantha Lake Hopkins has the most, with 1 of Tubulis GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.